Previous close | 11.01 |
Open | 11.01 |
Bid | 11.00 x 100 |
Ask | 11.50 x 900 |
Day's range | 10.95 - 11.10 |
52-week range | 6.08 - 14.00 |
Volume | |
Avg. volume | 32,121 |
Market cap | 72.193M |
Beta (5Y monthly) | 1.26 |
PE ratio (TTM) | N/A |
EPS (TTM) | -24.00 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 36.00 |
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. Recent Highlights: Announced entering into a strategic collaboration to develop an autologous folate receptor α (FRα)-CoStAR enhanced TIL for a potential investigator-initiated trial (IIT) in non-small cell lung ca
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.